TotalMarketCap

ArriVent BioPharma

AVBPNasdaq United StatesHealth CareBiotechnology: Pharmaceutical Preparations

Market cap

$602.540 M

$12.22 -9.41%

Close of 6 Nov 2026

As of 6 Nov 2026, ArriVent BioPharma (AVBP) has a market capitalization of $602.5M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$166.3M

Loss-making

Shares outstanding

49,307,729

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →
  1. #175Nuvectis PharmaNVCT$610.7M
  2. #176Kura OncologyKURA$606.3M
  3. #177ArriVent BioPharmaAVBP$602.5M
  4. #178Immix BiopharmaIMMX$597.3M
  5. #179Olema PharmaceuticalsOLMA$593.7M

What if ArriVent BioPharma were worth as much as…

Open the what-if tool →

Gold $28.2T

$572,666.28

Per share 46,863× higher

Bitcoin $1.53T

$30,985.98

Per share 2,536× higher

Apple $5.02T

$101,724.06

Per share 8,324× higher

Or at a round number

$1.00B$2.00B$5.00B$10.0B

Where these numbers come from

Share counts and financials for ArriVent BioPharma are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.